The Technical Analyst
Eliem Therapeutics, Inc. [ELYM]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Eliem Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
17.40% $3.98
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 110.32 mill |
| EPS: | -1.300 |
| P/E: | -3.06 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 27.72 mill |
| Avg Daily Volume: | 0.704 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.06 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.52x |
| Company: PE -3.06 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.44 (-13.64%) $-0.543 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.89 - 4.23 ( +/- 4.11%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-05 | Morisset Valerie | Buy | 17 847 | Common Stock |
| 2024-04-05 | Morisset Valerie | Sell | 17 847 | Stock Option (Right to Buy) |
| 2024-03-18 | Pimblett Emily | Buy | 40 000 | Restricted Stock Units |
| 2023-09-20 | Morisset Valerie | Buy | 15 297 | Common Stock |
| 2023-09-20 | Morisset Valerie | Buy | 5 431 | Common Stock |
| INSIDER POWER |
|---|
| 40.11 |
| Last 75 transactions |
| Buy: 17 601 902 | Sell: 12 020 423 |
Forecast:
16:00 - $4.07
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.07
Forecast 2: 16:00 - $4.07
Forecast 3: 16:00 - $4.07
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.98 (17.40% ) |
| Volume | 0.580 mill |
| Avg. Vol. | 0.704 mill |
| % of Avg. Vol | 82.37 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ELYM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ELYM
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
Last 10 Buy Signals
Latest Press Releases
2024-04-15 08:15:00 - Press Release
Shareholder Alert: Kaskela Law Llc Announces Investigation Of Eliem Therapeutics, Inc. (elym) And Encourages Investors To Contact The Firm
Philadelphia , april 15, 2024 /prnewswire/ -- kaskela law llc, announces that it is investigating eliem therapeutics, inc. (nasdaq: elym) ("eliem") on behalf of the company's shareholders. the investigation seeks to determine whether eliem issued false and misleading statements and/or failed to disclose material facts to investors in connection with recent corporate actions, thereby violating the securities laws and causing harm to the company's shareholders.
2024-04-11 08:30:00 - Press Release
Elym Stock Alert: Halper Sadeh Llc Is Investigating Whether The Merger Of Eliem Therapeutics, Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the merger of eliem therapeutics, inc. (nasdaq: elym) and tenet medicines, inc. is fair to eliem shareholders. halper sadeh encourages eliem shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. the investigation concerns whether eliem and its board violated the.
2024-04-11 07:00:00 - Press Release
Eliem Therapeutics Announces Agreement To Acquire Tenet Medicines And Concurrent $120 Million Private Placement
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life sciences investors combined company to focus on clinical development of lead product candidate, tnt119, in upcoming phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia companies to host webcast today, april 11, 2024 at 8:30 a.m. edt seattle and cambridge, united kingdom, april 11, 2024 (globe newswire) -- eliem therapeutics, inc. (nasdaq: elym) (“eliem”) and tenet medicines, inc...
2023-07-20 06:45:00 - Press Release
Eliem Therapeutics Announces Plans To Explore Strategic Alternatives
Seattle and cambridge, united kingdom, july 20, 2023 (globe newswire) -- eliem therapeutics, inc. (nasdaq: elym) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. eliem has engaged leerink partners to act as a strategic advisor in the process.
2022-11-30 07:00:00 - Press Release
Eliem Therapeutics At The 5th Annual Evercore Isi Healthconx Virtual Conference
Seattle and cambridge, united kingdom, nov. 30, 2022 (globe newswire) -- eliem therapeutics, inc. (nasdaq: elym), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that bob azelby, eliem's president and chief executive officer, will present at the 5th annual evercore isi healthconx virtual conference being held virtually on thursday, december 1, 2022 at 11:40 am et.
Latest News
2023-07-21 08:27:09 - Zacks Investment Research
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.
2023-07-20 08:04:20 - InvestorPlace
Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?
Eliem Therapeutics (NASDAQ: ELYM ) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives. Eliem Therapeutics came to this decision after completing a review of the company and its various programs.
2023-07-20 06:57:00 - Market Watch
Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself
Eliem Therapeutics Inc.'s stock ELYM, -4.76% soared 21% in premarket trade Thursday, after the biotech, which specializes in therapies for neuronal excitability disorders, said it is exploring its strategic options. The Seattle and Cambridge, U.K.-based company said it has halted the development of its Kv7 program, which was focused on treatments for pain and epilepsy.
2022-11-30 07:00:00 - GlobeNewsWire
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem's president and chief executive officer, will present at the 5th Annual Evercore ISI HealthCONx Virtual Conference being held virtually on Thursday, December 1, 2022 at 11:40 AM ET.
2022-06-21 12:01:02 - Benzinga
5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
2022-06-13 10:49:03 - Benzinga
5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
2022-05-16 11:38:03 - Benzinga
5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
2022-04-25 13:45:25 - GeekWire
Eliem Therapeutics shares sink more than 50% after lead program fails to show benefit in clinic
Shares of Eliem Therapeutics fell more than 50% Monday after reporting disappointing clinical data.
2022-04-25 09:06:07 - Benzinga
See Here Why Recently Listed Eliem Therapeutics Shares Are Plummeting
Eliem Therapeutics Inc's (NASDAQ: ELYM) ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) failed to achieve statistically significant separation from placebo on the trial's primary endpoint of daily pain score. The Company will longer pursue the.
2022-03-21 07:00:00 - GlobeNewsWire
Eliem Therapeutics to Present at Stifel's 2022 CNS Days
SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem's president and chief executive officer, will present at Stifel's 2022 CNS Days being held virtually on Tuesday, March 29, 2022 at 9:30 AM ET.